Close Menu

Resolution Biosciences

A study presented at the AACR meeting showed that Resolution's ctDx-Lung assay reported more oncogenic fusions than Guardant360 in NSCLC patients.

Investigators from the pharma concluded that most liquid biopsy false positives and negatives could be traced to technical specifics of individual tests.